Literature DB >> 15317667

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.

Pierre P Massion1, Peter M Taflan, Yu Shyr, S M Jamshedur Rahman, Pinar Yildiz, Bashar Shakthour, Mary E Edgerton, Matthew Ninan, Jeremiah J Andersen, Adriana L Gonzalez.   

Abstract

Signaling through the phosphatidylinositol 3-kinase (PI3-kinase) pathway has been associated with lung tumorigenesis. We examined the association between gene copy number of the PI3-kinase catalytic subunit alpha (PIK3CA) and phosphorylated Akt expression in invasive and preinvasive lung cancers. We sought to determine at what stage of tumor development gene copy number increase or phosphorylated Akt overexpression might affect tumor development. We assessed PIK3CA gene copy number by fluorescence in situ hybridization and expression of phosphorylated Akt by immunohistochemistry in 242 invasive and 43 preinvasive lung cancers and correlated our findings with clinical outcome. The PIK3CA was amplified in 70% of squamous carcinomas, 38% of large cell carcinomas, 19% of adenocarcinomas, and 67% of small cell lung cancers. Phosphorylated Akt overexpression was frequently observed, and strongly so in 12 to 17% of lung cancers depending on nuclear or cytoplasmic localization. Neither PIK3CA gene copy number nor phosphorylated Akt protein expression had prognostic significance. In preinvasive lesions, amplification of the PIK3CA and overexpression of phosphorylated Akt were associated with severe dysplasia and each other. These observations suggest frequent and early involvement of the PI3-kinase pathway in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317667     DOI: 10.1164/rccm.200404-487OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  47 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Authors:  Corey J Langer; Mary W Redman; James L Wade; Charu Aggarwal; Jeffrey D Bradley; Jeffrey Crawford; Philip J Stella; Mark H Knapp; Jieling Miao; Katherine Minichiello; Roy S Herbst; Karen Kelly; David R Gandara; Vassiliki A Papadimitrakopoulou
Journal:  J Thorac Oncol       Date:  2019-05-31       Impact factor: 15.609

4.  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Heather S Floyd; Joseph E Moore; Libyadda J Mosley; Ralph B D'Agostino; Mark J Pettenati; Mark Steven Miller
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-27       Impact factor: 4.219

5.  Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Authors:  Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.860

Review 6.  Lessons learned from next-generation sequencing in head and neck cancer.

Authors:  Myriam Loyo; Ryan J Li; Chetan Bettegowda; Curtis R Pickering; Mitchell J Frederick; Jeffrey N Myers; Nishant Agrawal
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

7.  Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

Authors:  Enrique Lerma; Lluis Catasus; Alberto Gallardo; Gloria Peiro; Carmen Alonso; Ignacio Aranda; Agusti Barnadas; Jaime Prat
Journal:  Virchows Arch       Date:  2008-08-05       Impact factor: 4.064

8.  Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung.

Authors:  J Matthew McDonald; Christopher E Pelloski; Alicia Ledoux; Menghong Sun; Gabriela Raso; Ritsuko Komaki; Ignacio I Wistuba; B Nebiyou Bekele; Ken Aldape
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

9.  Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.

Authors:  J Kikuchi; I Kinoshita; Y Shimizu; S Oizumi; M Nishimura; M J Birrer; H Dosaka-Akita
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

10.  VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.

Authors:  Chang-Han Chen; Jin-Mei Lai; Teh-Ying Chou; Cheng-Yu Chen; Li-Jen Su; Yuan-Chii Lee; Tai-Shan Cheng; Yi-Ren Hong; Chen-Kung Chou; Jacqueline Whang-Peng; Yu-Chung Wu; Chi-Ying F Huang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.